About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

FDA Investigates Deaths of Patients on Antipsychotic Drug

Two patients died days after receiving Zyprexa injections
WEDNESDAY, June 19 (HealthDay News) -- Following the deaths of two patients three to four days after receiving a dose of Zyprexa Relprevv (olanzapine pamoate) via intramuscular injection, the U.S. Food and Drug Administration is conducting an investigation into the possible cause.
The patients were well outside the three-hour window of monitoring required by the antipsychotic drug's Risk Evaluation and Mitigation Strategy (REMS), but were found to have very high blood levels of olanzapine after death.
In addition to the three-hour monitoring period, REMS protocol requires patients to receive injections only at REMS-certified facilities and to be accompanied home after the monitoring period. The drug's label warns against possible post-injection delirium sedation syndrome, in which the agent enters the blood too quickly and causes heavy sedation (possibly coma) and/or delirium.
According to the agency, "FDA is providing this information to health care professionals while it continues its investigation. If therapy with Zyprexa Relprevv is started or continued in patients, health care professionals should follow the REMS requirements and drug label recommendations. Patients and caregivers should talk to their health care professional(s) about any questions or concerns."
More Information (http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm?source=govdeliver )
Health Headlines
Athletic Trainers First Line of Treatment for Young Basketballers: StudyView in a lightbox
People Seek Out Health Info When Famous Person DiesView in a lightbox
Early Sign of Kidney Disease Often Ignored, Study SaysView in a lightbox
Research Shows Ways to Speed Stroke CareView in a lightbox
A Little Wine Might Help Kidneys Stay HealthyView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices